IOSR Journal Of Pharmacy and Biological Sciences (IOSR-JPBS)
e-ISSN:2278-3008, p-ISSN:2319-7676. Volume 21, Issue 4 Ser. 2 (July. – August. 2026), PP 21-25
www.Iosrjournals.Org

The Potential Of Organ-On-Chip Technology In Transforming Cancer Drug Development And Personalised Medicine: A Review

Author

Abstract
Cancer continues to be one of the leading causes of death worldwide, creating a major challenge for healthcare systems and researchers. Although advances in treatments such as targeted therapies and immunotherapy have improved patient outcomes, developing effective cancer treatments remains difficult due to the complexity and individual variation of tumours. Patients with the same cancer diagnosis may respond differently to identical therapies because of differences in tumour genetics, biological characteristics, and immune responses.
Traditional preclinical models, including two-dimensional (2D) cell cultures and animal studies, have played an important role in cancer research. However, these models often fail to accurately represent the complexity of human tumours, which can contribute to unsuccessful clinical trials and delays in developing new treatments.
This review examines the role of organ-on-chip technology in improving cancer drug development and supporting personalised medicine. Organ-on-chip systems combine human cells, microfluidic engineering, and tissue models to recreate key features of human organs and tumour environments. These platforms allow researchers to study cancer progression and evaluate treatment responses under conditions that more closely resemble the human body.
A literature review was conducted using scientific databases including PubMed, Google Scholar, and ScienceDirect to analyse the applications, benefits, and limitations of organ-on-chip technology. The evidence suggests that these systems could improve the accuracy of drug testing and contribute to more personalised treatment strategies. However, challenges such as high costs, lack of standardisation, and limited clinical validation currently restrict their widespread use.
Overall, organ-on-chip technology represents a valuable advancement in cancer research. Although it is unlikely to completely replace traditional models in the near future, it may serve as an important complementary tool for developing safer and more effective cancer therapies.

Date of Submission: 05-08-2026 Date of Acceptance: 15-08-2026

I. Introduction

Cancer remains one of the most challenging diseases in modern healthcare, affecting millions of individuals worldwide. Despite major progress in cancer diagnosis and treatment, including the development of targeted therapies and immunotherapies, achieving consistently successful outcomes remains difficult. A major reason for this challenge is the biological diversity of cancer; tumours can vary significantly between patients, meaning that a treatment effective for one individual may show limited benefits or cause unwanted effects in another.

The increasing recognition of differences between patients has highlighted the importance of personalised medicine. Rather than using a standard treatment approach for all patients with the same cancer type, personalised medicine aims to consider individual biological factors when selecting therapies. Differences in tumour genetics, cellular behaviour, and immune responses can strongly influence treatment effectiveness (Ingber, 2022).

Currently, cancer drug development relies heavily on preclinical models such as two-dimensional (2D) cell cultures and animal studies. While these methods have contributed significantly to understanding cancer biology, they have important limitations. Two-dimensional cultures allow researchers to observe cancer cells in controlled laboratory conditions but cannot fully reproduce the three-dimensional structure of tumours or the interactions between cancer cells and their surrounding environment (Sontheimer-Phelps et al., 2019). Similarly, animal models provide more complex biological systems but may not accurately predict human responses due to differences in physiology, metabolism, and immune function (Bhatia and Ingber, 2014).

These limitations create difficulties during the drug development process. Many treatments that demonstrate promising results in laboratory studies fail during later clinical trials because their effects in experimental models do not accurately reflect responses in humans. This contributes to increased costs, longer

development timelines, and delays in making new therapies available to patients.

The need for more accurate human-based models has encouraged the development of organ-on-chip technology. First introduced as a way to recreate human organ functions using microengineering approaches, organ-on-chip systems combine living cells with microfluidic devices and tissue engineering techniques to simulate aspects of human biology (Huh et al., 2011). Unlike traditional cell cultures, these models can reproduce features such as tissue organisation, fluid movement, and interactions between different cell types.

In cancer research, organ-on-chip platforms provide opportunities to study tumour development, metastasis, and treatment responses in a more realistic environment. By incorporating patient-derived cells, these systems may also contribute to personalised medicine by allowing researchers to investigate how individual tumours respond to different therapies before treatment decisions are made.

This review explores the extent to which organ-on-chip technology can transform cancer drug development and personalised medicine. It examines the limitations of current research models, the applications and advantages of organ-on-chip systems, and the challenges that must be addressed before their widespread use in clinical practice.

The aim of this review is to evaluate whether organ-on-chip technology can provide a more accurate and personalised approach to cancer research by examining its applications, advantages, and current limitations.

Research Question

To what extent can organ-on-chip technology address the limitations of conventional preclinical cancer models and contribute to advances in drug development and personalised medicine?

II. Methodology

This review was conducted as a literature-based study to evaluate the role of organ-on-chip technology in cancer drug development and personalised medicine. Scientific research articles and review papers were collected from established academic databases, including PubMed, Google Scholar, and ScienceDirect.

Relevant studies were identified using keywords such as “organ-on-chip technology”, “cancer-on-chip models”, “microfluidics”, “tumour microenvironment”, “drug development”, and “personalised medicine”. Peer-reviewed publications were prioritised to ensure that the information analysed was based on reliable scientific evidence.

The selected literature was examined according to several key themes: the limitations of conventional cancer research models, the applications of organ-on-chip systems in oncology, their potential advantages in drug development and personalised treatment, and the challenges affecting their implementation in healthcare.

The findings from these studies were compared and evaluated to determine whether organ-on-chip technology can provide a more accurate approach to cancer research and whether it has the potential to contribute to future personalised treatment strategies.

III. Findings And Discussion

Limitations of Current Cancer Research Models

The development of effective cancer treatments depends greatly on the ability of research models to accurately represent tumour behaviour within the human body. Traditionally, scientists have relied on two-dimensional (2D) cell cultures and animal models to understand cancer progression and test potential therapies. Although these approaches have provided valuable insights into cancer biology, they do not completely reflect the complexity of human disease.

Two-dimensional cell cultures involve growing cancer cells on flat laboratory surfaces. These models are relatively simple, cost-effective, and useful for studying basic cellular processes such as growth and drug response. However, they lack many characteristics of real tumours, including three-dimensional organisation, differences in nutrient availability, and interactions between cancer cells and surrounding tissues. As a result, drug responses observed in 2D cultures may not accurately represent how a treatment will behave within the human body.

Animal models provide a more complex biological environment and have contributed significantly to the development of cancer therapies. However, differences between animal and human physiology can limit their predictive accuracy. Variations in immune responses, metabolism, and tumour development may result in treatments appearing effective in animals but showing reduced success during human clinical trials. This contributes to increased research costs, longer development periods, and potential failure of drugs during later stages of testing.

These limitations are particularly important in cancer treatment because tumours are highly individual. Two patients diagnosed with the same cancer type may have different genetic mutations, tumour environments, and responses to therapy. Therefore, models that cannot accurately represent this variation may limit the ability to develop truly personalised treatments.

However, traditional models should not be considered ineffective. They remain important tools for understanding disease mechanisms and evaluating potential therapies. Instead, their limitations demonstrate the need for additional approaches that can provide more human-relevant information.

Organ-on-chip technology has emerged in response to this challenge by attempting to bridge the gap between simplified laboratory models and the complexity of human biology. By recreating important features of organs and tumour environments, these systems may provide researchers with a more accurate platform for studying cancer progression and treatment responses.

Potential of Organ-on-Chip Technology in Cancer Research

Organ-on-chip technology has emerged as an innovative approach to addressing some of the limitations associated with conventional cancer research models. These systems are miniature devices that combine human cells, microfluidic technology, and tissue engineering to recreate specific features of human organs and disease environments. Unlike traditional two-dimensional cultures, organ-on-chip models can reproduce aspects of three-dimensional tissue organisation, fluid movement, and interactions between multiple cell types, allowing researchers to study cancer in conditions that more closely resemble the human body.

One of the early developments that demonstrated the potential of this technology was the lung-on-chip model created by Huh et al. (2011). This system successfully recreated important features of human lung function by using microfluidic channels to simulate interactions between lung cells and blood vessels. Although this model was not specifically designed for cancer research, it demonstrated that engineered platforms could reproduce complex human biological processes and encouraged their application in disease modelling.

In cancer research, organ-on-chip technology has been particularly valuable for studying tumour progression and metastasis. Metastasis, the process by which cancer cells spread from their original location to other parts of the body, is responsible for the majority of cancer-related deaths. Understanding this process has been challenging because it involves interactions between tumour cells, blood vessels, surrounding tissues, and biochemical signals.

Bersini et al. (2014) developed a breast cancer-on-chip model to investigate how tumour cells interact with bone tissue during metastasis. Their research provided insights into the mechanisms involved in cancer spread and demonstrated how organ-on-chip systems can recreate specific disease environments that are difficult to study using conventional methods.

Another major advantage of these models is their ability to study the tumour microenvironment. Tumours do not exist independently; they interact continuously with surrounding cells, immune components, blood vessels, and extracellular structures. These interactions can influence tumour growth and determine how effectively a treatment works. Traditional laboratory models often simplify these conditions, whereas organ-on-chip systems allow researchers to include multiple biological components within a controlled environment.

For example, Hassell et al. (2017) developed a human lung cancer-on-chip model that reproduced features of lung cancer growth, tumour dormancy, and responses to different therapies. This study demonstrated that organ-on-chip platforms could provide a more detailed understanding of tumour behaviour and may improve the evaluation of potential treatments before they are tested in patients.

A significant application of organ-on-chip technology is improving cancer drug development. The process of developing new treatments is expensive and time-consuming, and many potential drugs fail during clinical trials despite showing promising results in early laboratory studies. One reason for this failure is that traditional models may not accurately predict how human patients will respond. By incorporating human cells and more realistic biological conditions, organ-on-chip systems may improve the prediction of drug effectiveness and toxicity.

Bhatia and Ingber (2014) suggested that microfluidic organ models could provide more reliable platforms for drug testing by recreating important aspects of human physiology. However, while these systems may improve early-stage drug evaluation, further research is required to determine how accurately they can predict long-term patient outcomes.

Beyond drug development, organ-on-chip technology may contribute significantly to personalised medicine. Since cancer varies considerably between individuals, a treatment approach that works for one patient may not produce the same results in another.

Patient-specific organ-on-chip models could potentially be created using a person's own tumour cells, allowing researchers to test multiple therapies and identify treatments that are more likely to be effective.

This approach could be particularly valuable for cancers where treatment selection is difficult due to tumour diversity. For example, rather than relying only on population-based clinical data, doctors may eventually be able to use patient-specific models as an additional source of information when making treatment decisions.

Despite this potential, organ-on-chip systems are not currently used as routine clinical tools. Their application in healthcare requires further validation to demonstrate that results obtained from these models

consistently reflect patient outcomes. Therefore, their current role is more likely to be as a complementary method alongside existing approaches rather than a complete replacement for traditional models.

Overall, organ-on-chip technology represents a significant advancement in cancer research by providing a more biologically realistic platform for studying tumours and testing treatments.

Although challenges remain before widespread clinical adoption, these systems may contribute to a future where cancer therapies are developed more efficiently and tailored more closely to individual patients.

Challenges and Future Possibilities

Although organ-on-chip technology has demonstrated considerable potential in cancer research, several challenges must be addressed before it can become a widely adopted tool in drug development and clinical practice.

One of the major limitations is the technical complexity involved in creating and maintaining these systems. Developing accurate organ-on-chip models requires specialised equipment, advanced knowledge of microengineering, and collaboration between different scientific fields, including biology, medicine, and engineering. These requirements can increase costs and may limit access for smaller research laboratories.

Another important challenge is the lack of standardisation between different organ-on-chip platforms. Researchers may use different materials, designs, cell sources, and experimental conditions, which can make it difficult to compare results across studies. Establishing consistent protocols and validation methods will be essential to ensure that these models produce reliable and reproducible outcomes.

Furthermore, although organ-on-chip systems can recreate several aspects of human biology, they cannot completely represent the complexity of the entire human body. Cancer development and treatment responses are influenced by interactions between multiple organs, genetic factors, lifestyle, and long-term biological changes. Current models are generally designed to study specific aspects of disease rather than the complete physiological environment experienced by a patient.

A further consideration is whether results obtained from organ-on-chip models can consistently predict clinical outcomes. While many studies have shown that these systems can reproduce important features of tumour behaviour, fewer studies have demonstrated that they can accurately guide treatment decisions in real patients. Large-scale validation studies will therefore be necessary before organ-on-chip technology can become part of routine healthcare.

Despite these challenges, continued developments in biotechnology and computational approaches may expand the capabilities of organ-on-chip systems. The integration of artificial intelligence (AI) could allow researchers to analyse complex biological data, identify patterns in treatment responses, and improve predictions of drug effectiveness. Additionally, the development of multi-organ "body-on-chip" systems may allow scientists to investigate how cancer treatments affect different organs simultaneously, providing a more complete understanding of potential benefits and side effects.

In the future, organ-on-chip technology may become an important supporting tool in precision medicine by providing additional information to guide treatment decisions. However, it is important that expectations remain realistic; these systems are unlikely to replace all existing research methods but may instead work alongside traditional approaches to improve the accuracy of cancer research.

IV. Conclusion

This review demonstrates that organ-on-chip technology has the potential to significantly influence cancer drug development and personalised medicine by addressing several weaknesses of conventional preclinical models. Traditional approaches, including two-dimensional cell cultures and animal studies, have contributed greatly to cancer research but often fail to accurately reproduce the complexity of human tumours and individual treatment responses.

Organ-on-chip systems provide an alternative approach by combining human cells, microfluidic technology, and tissue engineering to recreate important features of tumour environments. Their ability to model cancer progression, investigate treatment responses, and potentially incorporate patient-specific cells makes them a valuable advancement in modern oncology research.

However, the current evidence suggests that organ-on-chip technology should not yet be viewed as a complete replacement for existing models. Limitations including technical complexity, high costs, lack of standardisation, and insufficient clinical validation continue to restrict widespread implementation. Further research is required to determine how effectively these systems can predict patient outcomes and improve treatment decisions.

Therefore, the success of organ-on-chip technology will depend not only on technological improvements but also on demonstrating clear clinical benefits compared with existing approaches.

Overall, organ-on-chip technology represents an important step towards more personalised and efficient cancer care. While it remains a developing field, its ability to provide more human-relevant models could

improve the process of drug discovery, reduce failures during clinical development, and contribute to a future where cancer treatments are increasingly tailored to individual patients.

References

[1]. Bersini, S., Jeon, J.S., Dubini, G., Charest, J.L., Moretti, M. And Kamm, R.D. (2014) 'A Microfluidic 3D In Vitro Model For Specificity Of Breast Cancer Metastasis To Bone', Biomaterials, 35(8), Pp.2454–2461. Doi:10.1016/J.Biomaterials.2013.11.050.

[2]. Bhatia, S.N. And Ingber, D.E. (2014) 'Microfluidic Organs-On-Chips', Nature Biotechnology, 32, Pp.760–772. Doi:10.1038/Nbt.2989.

[3]. Esch, E.W., Bahinski, A. And Huh, D. (2015) 'Organs-On-Chips At The Frontiers Of Drug Discovery', Nature Reviews Drug Discovery, 14, Pp.248–260. Doi:10.1038/Nrd4539.

[4]. Hassell, B.A., Goyal, G., Lee, E. Et Al. (2017) 'Human Organ Chip Models Recapitulate Orthotopic Lung Cancer Growth, Therapeutic Responses, And Tumor Dormancy In Vitro', Cell Reports, 21(2), Pp.508–516. Doi:10.1016/J.Celrep.2017.09.043.

[5]. Huh, D., Hamilton, G.A. And Ingber, D.E. (2011) 'From 3D Cell Culture To Organs-On-Chips', Trends In Cell Biology, 21(12), Pp.745–754. Doi:10.1016/J.Tcb.2011.09.005.

[6]. Ingber, D.E. (2022) 'Human Organs-On-Chips For Disease Modelling, Drug Development And Personalized Medicine', Nature Reviews Genetics, 23, Pp.467–491. Doi:10.1038/S41576-022-00459-Y.

[7]. Low, L.A., Mummery, C., Berridge, B.R., Austin, C.P. And Tagle, D.A. (2021) 'Organs-On-Chips: Into The Next Decade', Nature Reviews Drug Discovery, 20, Pp.345–361. Doi:10.1038/S41573-020-0079-7.

[8]. Sontheimer-Phelps, A., Hassell, B.A. And Ingber, D.E. (2019) 'Modelling Cancer In Microfluidic Human Organs-On-Chips', Nature Reviews Cancer, 19, Pp.65–81. Doi:10.1038/S41568-019-0150-7.

[9]. Trujillo-De Santiago, G., Flores-Garza, B., Tovar-Morales, C. Et Al. (2019) 'The Tumor-On-Chip: Recent Advances In Cancer Research', Advanced Healthcare Materials, 8(15). Doi:10.1002/Adhm.201801584.